Investigation of Blood Count-Based Inflammatory Biomarkers as Predictors of Response to Dupilumab Treatment in Patients with Chronic Rhinosinusitis with Nasal Polyps
Pretreatment eosinophil count may serve as a potential biomarker for predicting nasal polyp reduction in dupilumab treatment of CRSwNP. Other CBC-based inflammatory markers did not show significant predictive value. Further prospective studies are needed to validate these findings and explore additional, reliable biomarkers to optimize treatment outcomes for CRSwNP patients.
Authors
- P Kiss (ORCID: https://orcid.org/0000-0001-9187-2063)
- Clemens Holzmeister (ORCID: https://orcid.org/0000-0003-2835-5121)
- Michael Habenbacher
- Jakob Pock
- Alexandros Andrianakis (ORCID: https://orcid.org/0000-0002-2530-9931)
- Ulrich Moser (ORCID: https://orcid.org/0000-0002-2095-3453)
- Ahmed Abaira
- Angelika Lang
- Katharina Walla
Institutions
- Medical University of Graz (AT)
Publication Details
- Journal
- Pharmaceutics
- Published
- 2024-10-25
- DOI
- https://doi.org/10.3390/pharmaceutics16111370
- Citations
- 6
- Primary Topic
- Sinusitis and nasal conditions
- Type
- article
- Field-Weighted Citation Impact
- 3.48